JP2020536966A5 - - Google Patents

Download PDF

Info

Publication number
JP2020536966A5
JP2020536966A5 JP2020541834A JP2020541834A JP2020536966A5 JP 2020536966 A5 JP2020536966 A5 JP 2020536966A5 JP 2020541834 A JP2020541834 A JP 2020541834A JP 2020541834 A JP2020541834 A JP 2020541834A JP 2020536966 A5 JP2020536966 A5 JP 2020536966A5
Authority
JP
Japan
Prior art keywords
pharmaceutically acceptable
pharmaceutical composition
antibiotic
optionally substituted
zinc
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020541834A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020536966A (ja
JP7514763B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/AU2018/051116 external-priority patent/WO2019071325A1/en
Publication of JP2020536966A publication Critical patent/JP2020536966A/ja
Publication of JP2020536966A5 publication Critical patent/JP2020536966A5/ja
Priority to JP2024040061A priority Critical patent/JP2024073569A/ja
Application granted granted Critical
Publication of JP7514763B2 publication Critical patent/JP7514763B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020541834A 2017-10-13 2018-10-12 亜鉛イオノフォアおよびその使用 Active JP7514763B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024040061A JP2024073569A (ja) 2017-10-13 2024-03-14 亜鉛イオノフォアおよびその使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2017904135A AU2017904135A0 (en) 2017-10-13 Compositions and their uses
AU2017904135 2017-10-13
PCT/AU2018/051116 WO2019071325A1 (en) 2017-10-13 2018-10-12 ZINC IONOPHORES AND USES THEREOF

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024040061A Division JP2024073569A (ja) 2017-10-13 2024-03-14 亜鉛イオノフォアおよびその使用

Publications (3)

Publication Number Publication Date
JP2020536966A JP2020536966A (ja) 2020-12-17
JP2020536966A5 true JP2020536966A5 (enExample) 2021-11-18
JP7514763B2 JP7514763B2 (ja) 2024-07-11

Family

ID=66100161

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020541834A Active JP7514763B2 (ja) 2017-10-13 2018-10-12 亜鉛イオノフォアおよびその使用
JP2024040061A Withdrawn JP2024073569A (ja) 2017-10-13 2024-03-14 亜鉛イオノフォアおよびその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024040061A Withdrawn JP2024073569A (ja) 2017-10-13 2024-03-14 亜鉛イオノフォアおよびその使用

Country Status (6)

Country Link
US (1) US20200261440A1 (enExample)
EP (1) EP3694515A4 (enExample)
JP (2) JP7514763B2 (enExample)
CN (1) CN111787921A (enExample)
AU (1) AU2018348796B2 (enExample)
WO (1) WO2019071325A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR3114742A1 (fr) * 2020-10-04 2022-04-08 Bruno Eto Composition pharmaceutique ou diététique pour bloquer la synthèse des peptides par les ribosomes.
AU2022380979A1 (en) 2021-11-02 2024-06-06 Flare Therapeutics Inc. Pparg inverse agonists and uses thereof
CN116726145A (zh) * 2022-03-04 2023-09-12 海南普利制药股份有限公司 一种稳定的酯肽类药物组合物
EP4565234A1 (en) * 2022-08-01 2025-06-11 Griffith University Antibacterial compound pbt2
CN120695002A (zh) * 2025-06-24 2025-09-26 南方医科大学南方医院 Pbt2在制备抗白念珠菌生物膜药物中的应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5696083A (en) * 1992-11-10 1997-12-09 Olin Corporation Personal care composition containing pyrithione and polymyxin
AU2002950217A0 (en) 2002-07-16 2002-09-12 Prana Biotechnology Limited 8- Hydroxy Quinoline Derivatives
DK1898909T3 (en) * 2005-06-28 2017-02-06 Janssen Pharmaceutica Nv QUINOLIN DERIVATIVES AS ANTIBACTERIAL AGENTS
WO2009140215A2 (en) * 2008-05-11 2009-11-19 Geraghty, Erin Method for treating drug-resistant bacterial and other infections with clioquinol, phanquinone, and related compounds
US20110189260A1 (en) * 2008-05-30 2011-08-04 University Of Cincinnati Use of zinc chelators to inhibit biofilm formation
ES2749223T3 (es) * 2013-04-16 2020-03-19 Univ Cincinnati Composiciones antimicrobianas de antibióticos aminoglicosídicos y quelantes de iones de zinc
GB201317619D0 (en) * 2013-10-04 2013-11-20 Uni I Oslo Compounds
CN107896480A (zh) * 2015-06-23 2018-04-10 詹森药业有限公司 食品准许的抗微生物剂和吡硫锌的组合
US11008290B2 (en) * 2015-09-24 2021-05-18 University Of Florida Research Foundation, Incorporated Halogenated quinoline derivatives as antimicrobial agents

Similar Documents

Publication Publication Date Title
JP2020536966A5 (enExample)
CN105246476B (zh) 含噁唑烷酮-喹诺酮的联合疗法在治疗细菌感染中的应用
JP2013523761A5 (enExample)
US11559514B2 (en) Compositions and methods of use of antibacterial drug combinations
JP2015528468A5 (enExample)
JO3588B1 (ar) مشتقات 3-تترازوليل -بنزين- 1، 2-ثنائي سلفوناميد كمثبطات ميتالو -بيتا- لاكتاماز
JP2010527346A5 (enExample)
RU2671485C2 (ru) Антибиотические композиции тазобактама аргинина
Brook Penicillin failure in the treatment of streptococcal pharyngo-tonsillitis
HRP20210484T1 (hr) Antimikrobna sredstva koja se temelje na imidazolu
JP6480870B2 (ja) 細菌感染を処置するための組成物および方法
Bosso The antimicrobial armamentarium: evaluating current and future treatment options
JP2008524204A (ja) 感染の処置に全面的解決を与えるための抗生物質の組合せ
JP2024009968A5 (enExample)
JP5276653B2 (ja) カルバペネム類を含む殺菌性抗mrsa活性医薬組成物
JP2019534289A5 (enExample)
JP2021501783A5 (enExample)
JP2016510749A5 (enExample)
Bhalla Faropenem, a stable and orally bioavailable β-lactam, to counteract resistant pathogens and infectious diseases. A narrative review
Watanabe et al. Comparative in vitro activity of carbapenem antibiotics against respiratory pathogens isolated in recent years
Asif A mini review on the study of new broad‐spectrum antimicrobial fluoroquinolone JNJ‐Q2
JPWO2019169479A5 (enExample)
CN100519533C (zh) 5-芳胺喹啉-7,8-二酮类衍生物及其在制备抗菌药物中的应用
Huband et al. In Vitro Activity of Omadacycline and Comparator Compounds Against Gram-positive Isolates Collected in the USA During 2016 as Part of a Global Surveillance Program
Sader et al. Antimicrobial activity of ceftaroline and comparator agents against contemporary (2010) Staphylococcus aureus isolates from Europe and South Africa